By Nathalie Cazeau - Member of the Paris Bar
The current geopolitical situation,
particularly the closure of strategic shipping
routes, raises questions about the resulting
supply tensions and their impact on the
relationships between subcontractors
and prime contractors. This article aims
to provide an overview of the main legal
aspects and issues arising from this
exceptional situation, which has significant
repercussions for subcontractors and
prime contractors alike
Read in the digital edition
- PHARMAnetwork magazine n° 68, page 60
By Nathalie Cazeau - Member of the Paris Bar
Outsourcing has become an essential strategic
lever in the pharmaceutical industry. Whether it
is galenic development, analysis, manufacturing,
or packaging, clients outsource many stages of
the drug life cycle.
But this outsourcing raises a crucial legal and
economic question: who owns the results
generated by the service? And, more specifically,
do these results always have high intellectual
property value, or are they simply technical
executions without any original or protectable
creation? The answer depends largely on the
nature of the contract i.e., whether it concerns
development or manufacturing, and, as is often
the case, on the legal context in which the issue
is addressed
Read in the digital edition
- PHARMAnetwork magazine n° 67, page 56
By Nathalie Cazeau - Member of the Paris Bar
In a constantly evolving pharmaceutical
environment, marked by intensifying regulatory
requirements and industrial challenges, Contract
Development and Manufacturing Organizations
(CDMOs) now occupy a strategic position
within the pharmaceutical value chain. As
close partners of pharmaceutical companies,
they are entrusted with increasingly extensive
outsourcing missions, covering both drug
development and production, making them
essential links in terms of innovation and supply
procurement.
Read in the digital edition
- PHARMAnetwork magazine n° 67, page 58
By Nathalie Cazeau - Member of the Paris Bar
In the pharmaceutical sector, the relationship between contracting laboratories and Contract Development and Manufacturing Organizations (CDMOs) is undergoing significant
change under the pressure of globalized logistics challenges,
increasingly stringent regulatory frameworks, and increased
competition.
The purchasing contract, long perceived
as a simple tool for setting prices and quality, now takes
on a strategic dimension: it must anticipate the diversity
and volatility of order flows that punctuate industrial activity.
This paradigm shift requires thinking of the contract
as a sophisticated instrument capable of mitigating uncertainties surrounding production volumes, delivery times,
and the allocation of production resources, to reduce the
risks of financial imbalance or execution failure, major factors in disputes and breaches of trust.
Read in the digital edition
- PHARMAnetwork magazine n° 67, page 64
By Nathalie Cazeau - Member of the Paris Bar
As mentioned in our previous articles in this magazine,
the manufacturing agreement is the perfect example of
an industrial partnership between two companies, in which
sustainability and stability are essential issues for both part
ner companies.
This contract, whose legal qualification combines the sale
and the provision of services, is based primarily on the sale by
the manufacturer of a pharmaceutical specialty developed on
behalf of the client.
Therefore, one of the essential clauses in the contract of
course concerns the definition of the price of the specialty
being manufactured, how it is determined (with the details
of its components, where applicable) and, above all, the price
revision mechanisms
Read in the digital edition
- PHARMAnetwork magazine n° 62, page 54
By Nathalie Cazeau - Member of the Paris Bar
The MSA is the perfect example of an industrial partner
ship between two companies, whose continuity and sta
bility are essential issues for both partners.
It may involve the installation of dedicated production
lines and making costly investments for the subcontractor.
It can also depend on regulatory approvals obtained after
several months, which represent a significant challenge for
the subcontractor’s turnover.
The termination or transfer of
this contract, with its substantial economic and industrial
implications, is inevitably a complex matter, one that the
parties cannot overlook when signing the contract.
This raises the question of how best to manage the dura
tion, termination and transfer of these contracts legally, pre
cisely in relation to the economic and industrial context in
which the parties operate.
Read in the digital edition
- PHARMAnetwork magazine n° 61, page 54
By Nathalie Cazeau - Member of the Paris Bar
How can we best understand the negotiation and drafting of a development contract in the
pharmaceutical sector? This contract, which is very specific to this sector, must be drafted
very carefully, taking into account the variety of situations that we encounter, and the
economic and financial issues that are often decisive. This is a perfect example of the need
to reconcile technical and professional skills, and legal skills.
The development contract is a crucial, and often decisive, stage in a project to manufacture
and market a patent medicine.
Read in the digital edition
- PHARMAnetwork magazine n° 60, page 30
